WCLC 2024 – Gerrina Ruiter

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Gerrina Ruiter dives into the exciting world of HER2, exploring why it poses a tricky challenge in treating NSCLC, highlights the promising findings of the HER2 tyrosine kinase inhibitor zongertinib and shares insights on other notable innovations on the horizon in the field of HER2 inhibition.

Here is the full WCLC 2024 report.